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Background: Human polyomaviruses (HPyV) infections cause mostly unapparent or mild primary infections,
followed by lifelong nonpathogenic persistence. HPyV, and specifically JCPyV, are known to co-diverge with their
host, implying a slow rate of viral evolution and a large timescale of virus/host co-existence. Recent bio-informatic
reports showed a large level of peptide homology between JCPyV and the human proteome. In this study, the
antibody response to PyV peptides is evaluated.
Methods: The in-silico analysis of the HPyV proteome was followed by peptide microarray serology. A
HPyV-peptide microarray containing 4,284 peptides was designed and covered 10 polyomavirus proteomes.
Plasma samples from 49 healthy subjects were tested against these peptides.
Results: In-silico analysis of all possible HPyV 5-mer amino acid sequences were compared to the human
proteome, and 1,609 unique motifs are presented. Assuming a linear epitope being as small as a pentapeptide, on
average 9.3% of the polyomavirus proteome is unique and could be recognized by the host as non-self. Small t Ag
(stAg) contains a significantly higher percentage of unique pentapeptides. Experimental evidence for the presence
of antibodies against HPyV 15-mer peptides in healthy subjects resulted in the following observations: i) antibody
responses against stAg were significantly elevated, and against viral protein 2 (VP2) significantly reduced; and ii)
there was a significant correlation between the increasing number of embedded unique HPyV penta-peptides
and the increase in microarray fluorescent signal.
Conclusion: The anti-peptide HPyV-antibodies in healthy subjects are preferably directed against the penta-peptide
derived unique fraction of the viral proteome.
Keywords: Human polyomaviruses, Peptide microarray, Pentapeptides epitopesBackground
The Polyomaviridae are a family of non-enveloped circular
double-stranded DNA viruses. The Polyomaviridae Study
Group of the International Committee on Taxonomy of
Viruses (ICTV) has proposed that the Polyomaviridae
family will be comprised of three genera: two genera
containing mammalian viruses (Orthopolyomavirus and
Wukipolyomavirus) and one genus containing avian
viruses (Avipolyomavirus) [1]. Besides the HPyVs that
were discovered more than 40 years ago (JCPyV and
BKPyV), several new polyomaviruses have been discovered* Correspondence: lstuyver@its.jnj.com
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reproduction in any medium, provided the orover the last 7 years in human clinical samples, namely
WUPyV [2], KIPyV [3], MCPyV [4], TSPyV [5], HPyV6
and HPyV7 [6], HPyV9 [7], HPyV10 [8] and MWPyV [9],
STLPyV [10], and HPyV12 [11]. Based on pairwise per-
centage identity of the viral protein-1 (VP1) open reading
frame, members of the same species have more than 90%
identity, between species identity ranged from 61 to 85%,
and viruses belonging to different genera have less than
61% identity [6]. The primate virus SV40 has been
detected in human samples [12], but there is inadequate
evidence about the relationship to human carci-
nogenesis [13]. The recently discovered human virus
(HPyV9) is closely related to the African Green Monkey
Lymphotropic PyV (LPyV) [7,14], and this discoveryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dence that LPyV-like virus infections may occur in
humans [15,16].
Multiple methods have been used to measure anti-
bodies to polyomavirus virions. The most common
method is based on the use of baculovirus-expressed
VP1 virus-like-particles (VLP) in an enzyme immuno
assay (EIA) [17-20]. Additionally, there are E.coli-
expressed VP1 proteins that do not form VLP, but ra-
ther pentameric VP1 capsomers either used in an EIA,
or in a Luminex multiplex platform [15,21]. Currently,
the STRATIFY JCPyV ELISA is the only Food and Drug
Administration (FDA) approved assay for JCPyV [22],
while all the others are lab developed tests for ‘research
use only’. To a large extent, the immune response mea-
sured in these VLP-, or capsomer-based assays is di-
rected against conformational epitopes [23]. There are
few peptide EIA described that are presumably detecting
linear epitopes/mimitopes [12].
Since there is considerable homology at the VP1 region
for the human PyV belonging to the same genus, it does
not come as a surprise that there is a considerable cross-
reactivity in serological assays [23]. For example, sero-
logical cross-reactivity in the alpha-PyV is explained by
77% amino acid identity between JCPyV and SV40, 83%
between BKPyV and SV40, and 80% between JCPyV and
BKPyV. The availability of VLP of the different PyV allows
to conduct inhibition studies, and find virus specific-
antibodies [16,23].
By using phylogenetic methods, the worldwide distri-
bution of JCPyV genotypes was found to mirror the mi-
grations and genetics of the human family [24,25].
JCPyV, and most likely many other polyomaviruses, have
co-evolved with their hosts over long evolutionary time-
scale, which allowed mechanisms of immune-evasion to
be evolved. Indeed, analysis of JCPyV polyprotein for
peptide sharing with the human proteome revealed that
the virus has hundreds of pentapeptides sequences in
common with the human proteins [26]. This type of
immune-evasion may contribute to the asymptomatic
character of the primary infection, and subsequent la-
tency. But, several sequence domains that are JCPyV-
unique were also detected [26]. The role of these unique
domains in the mechanisms and molecular basis for pol-
yomavirus reactivation and pathogenesis remains unclear.
Since there is a great overlap in pentapeptide sequen-
ces between the human genome and the PyV genome, it
is of particular interest to distinguish between domains
that are recognized by auto-antibodies, and other do-
mains that are characteristic for a polyomavirus infec-
tion. Therefore, in this study, we explored the following
items: i) is there an immune response to HPyV-epitopes
presented as peptides; ii) how do these peptide epitopes
relate to unique viral domains with no overlap with thehuman proteome. The answers to these questions could
help in understanding the immune response to HPyV in-
fections, the discrimination between ‘self ’ and ‘non-self ’,
the status of an uninfected individual, and hopefully
contribute to the unraveling of the mechanisms under-
lying virus reactivation.
Results
Polyomavirus peptide similarity with the human
proteome
The HPyV reference sequence database was retrieved
from NCBI. The viral proteins LTAg, stAg, VP1, and
VP2 for 11 HPyV were cut in silico into either 5-mer
(with 4 amino acid (aa) overlap), 6-mer (with 5 aa over-
lap), or 7-mer (with 6 aa overlap) peptides. This resulted
into 17,396 penta-peptides, 17,347 hexa-peptides, and
17,304 hepta-peptides. These small peptides were
presented to the complete human proteome (20,227
proteins in http://www.uniprot.org/faq/48) for pairwise
comparison (in order to identify correct matches).
A total of 1,609 (9.25%) penta-peptides had no match in
the human genome, while for the hexa- and hepta-
peptides, the numbers rose to 12,064 (69.5%), and 16,679
(96.39%), respectively. The distribution expressed in num-
ber of matches of hexa- and hepta-peptides follows a simi-
lar pattern, but a very different one as compared to the
pentapeptides (Figure 1a). The degree of uniqueness and
the sharp drop with increasing number of matches on the
human genome suggest that hexa- and hepta-peptides are
likely to be HPyV-specific. Consequently, if an epitope
would encompass 6 or more amino acids in one continu-
ous stretch, this epitope is also likely to be HPyV-specific.
However, for the penta-peptides, the distribution is ra-
ther different, as only 9.25% of the peptides were found
to be unique to polyomaviruses. The remaining 90.75%
of peptides have at least one or more matches with the
human proteome. There were 939 penta-peptides, 11
hexa-peptides, and 2 hepta-peptides with more than 30
matches in the human proteome (not shown); these motifs
were often stretches containing 3 to 6 identical amino acids,
like for example hexapeptide AAAAAA in the HPyV7 VP1
carboxyterminal region (… 356SSNAAAAAAKISVA370P…),
which was found 2,364 times in the human proteome.
The 1,609 penta-peptides with no match in the
human proteome were distributed as follows: JCPyV:
n = 134, BKPyV: n = 155, SV40: n = 150, KIPyV: n = 155,
WUPyV: n = 121, MCPyV: n = 147, MWPyV: n = 150,
TSPyV: n = 160, HPyV6: n = 148, HPyV7: n = 156, and
HPyV9: n = 133. When ranked per protein, there were
700, 343, 326, 231, and 9 pentapeptides for LTAg, stAg,
VP1, VP2, and agno, respectively with no match in the
human proteome (Additional file 1). From the above
data, one can calculate the numbers of peptides with
“no match” in the human proteome, and this is
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Figure 1 In silico analysis of the HPyV unique peptide sequences as compared to the human proteome. a. The polyomavirus proteome
was presented as 17,396 pentapeptides, 17,347 hexapeptides, and 17,304 heptapeptides to the complete human proteome. The number of
polyomavirus peptides with zero up to 30 matches in the human genome are given, with values for hexa- and hepta-peptides numbers on the
primary Y-axis (left), while values for pentapeptides are shown on the secondary Y-axis (right). b. Percentage of HPyV penta-peptides with no
match in the human proteome. The number of “zero hit” pentapeptides was divided by the total number of amino acids for each viral protein
(protein length differ between viral species). Each data-cluster contains 11 data-points, corresponding to the following viruses: JCV (□, n = 134
unique pentapeptides), BKV (○, n = 155), SV40 (n = 150), KIV (△, n = 155), WUV (▽, n = 121), MCV (♢, n = 147), MWV (✖, n = 150), TSV (n = 160),
HPyV6 (✚, n = 148), HPyV7 (❋, n = 156), and HPyV9 (◗, n = 133). The means (16.6%; 9.3%; 7.8%; and 6.2%; respectively) with standard deviations
are shown.
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peptides per virus per protein (Figure 1b). This figure
shows that the mean of 16.6% for all PyV in the case of
stAg is significantly higher (p < 0.0001) than the 9.3%;
7.8%; and 6.2%; respectively for LTAg, VP1, and VP2.
Differences between the other means, except VP1 versus
VP2, were also found to be significantly different from
each other (p < 0.05).Array results
A total of 4,284 peptides were incubated in a peptide
microarray format with plasma samples from 49 HVs,
resulting in 209,916 data points. This population has a
median log2 (signal/control) value of 1.683 (min: -1.222,
25th: 1.135; 75th: 2.50; 90th: 3.319; and max: 6.909). We
used the median values of 49 HV data points for each
peptide to generate the figures used in this article. On
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were obtained: minimum: 0.089; 25th percentile: 1.281;
median: 1.593; 75th percentile: 2.129; maximum: 4.659;
mean: 1.778; standard deviation: 0.663; standard error:
0.010; the lower 95% confidence interval (CI) of mean:
1.758; and the upper 95% CI of mean: 1.798. The distri-
bution of the signal intensity for the 10 different viruses
did not result in any specific observation (data not
shown). But when analyzing the 5 different proteins
(LTAg, stAg, VP1, VP2, and agnoprotein) that were
present as peptides on the microarray, it was surprising
to see that antibody responses to stAg peptide were sig-
nificantly elevated (p = 3.45E-23), but also that the anti-
peptide antibody responses for VP2 were significantly
less abundant (p = 4.44E-16) (Figure 2).
Correlation between ‘unique polyomavirus peptides (not
present in the human proteome)’ and ‘peptide microarray
results’
Linear peptide epitopes are most frequently between 7 – 9
amino acids long (range 4 – 12) [27]. We focused on 5- to
7-mer peptides. Figure 1 illustrated already that most of
the hexa- and hepta-peptides are virus-specific, and in
these cases, linear epitopes would likely be virus-specific.
The analysis of the 5-mer peptides is less virus-restricted.
Since the microarray peptides were 15-mers, this means
that up to 11 5-mer epitopes could be present on one sin-
gle peptide. Some of these 11 epitopes might be virus-
specific, but others might have identical motifs in the
human genome.
Therefore, results from the 4,284 peptides on the
microarray were interpreted as a summary signal of 11Figure 2 Distribution of the polyomavirus peptide microarray signals
expressed as log2(signal of sample/signal of the no-sample control), making
median: 1.593 (dashed line); 75th percentile: 2.129 (dotted line). The followi
found: 1.68, 2.33, 1.58, 1.33, and 1.41. The median value from one protein w
Rank test for two samples”. The estimated difference between the medians
(LCI) and upper (UCI) 95% confidence intervals, and the p-values are as foll
stAg – others: 0.76, LCI: 0.587, UCI: 0.866, p = 3.45E-23; 3) VP1 – others: -0.0
UCI: -0.260, p = 4.44E-16; and 5) agno – others: -0.20, LCI: -0.323, UCI: 0.1295-mer peptides, under the assumption that microarray
peptides with viral-specific 5-mer epitopes would result
in higher signals. As can be deduced from Figure 3,
there was indeed a correlation between the ‘number of
embedded penta-peptides with no human homologue’ in
the microarray peptides and the strength of the signal
obtained with human HS plasma. Based on the linear re-
gression analysis using all data-points, there was a step-
wise increase in expression value as given by the
following formula: y = 0.17× + 1.55 (Table 1). The diffe-
rence between each subset is significant (p < 0.05). The
95% CI on the slope were within 0.14 and 0.18. In
addition, Table 1 provides the slopes and intercepts for
each protein and virus separated. When ranking the
groups according to the steepest slope, KIPyV and
JCPyV were seen as the 2 most important contributors
to the overall slope. Despite the fact that agno had only
a small amount of unique peptides, the slope turned out
to be very steep. In contrast, the slope was rather shal-
low for BKPyV and SV40, and stAg. The Y-intercept was
highest for stAg (2.09, in agreement with the observation
in Figure 2). In conclusion, microarray peptides with one
or more embedded polyomavirus penta-peptides with no
human homologue showed a higher signal on the micro-
array, and therefore are likely to represent viral-specific
epitopes.
Discussion
The results of the human proteome scan can be summa-
rized as follows; i) if 5-mer peptides are considered, up to
90.75% of the viral proteome is similar to the human
proteome, and therefore seen as “self”, but the percentagein function of the the viral proteins. Values on the Y-axis are
a value of 0 = background. From the statistics for all 4284 datapoints:
ng median values, respectively from left (LTAg) to right (agno), were
as compared to the median value all other proteins by using a “Linear
(= median test protein minus median all other datapoints), the lower
ows: 1) LTAg – others: 0.10, LCI: 0.032, UCI: 0.157, p = 0.0006; 2)
5, LCI: -0.108, UCI: -0.005, p = 0.02712; 4) VP2 – others: -0.31, LCI: -0.360,
, p = 0.2727.
Figure 3 Correlation plot between the median HS microarray signals in function of the amount of pentapeptides with no match in the
human proteome. There were in total 2276, 980, 495, 269, 136, 70, 36, 18, and 4 ‘15-mer’ peptides with, respectively, 0, 1, 2, 3, 4, 5, 6, 7, and 8
5-mer peptide “no matches” in the human proteome. The dotted/dashed lines represent, respectively, the 75th percentile at 2.129, and the
median at 1.593 of the complete population. The boxplot median values are, respectively, 1.449, 1.681, 1.820, 2.043, 1,979, 2.661, 2.539, 2.788, and
3.265. All data-points were used in a robust linear regression analysis tool to calculate the slope (0.17), Y intercept (1.55) and the lower (0.14) and
upper (0.18) confidence intervals on the slope. The linear regression line is drawn as in interrupted line through the boxplots.
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with 7-mer peptides [26]; and ii) with an average of 16.6%
of unique pentapeptides, stAg is significantly less recog-
nized as ‘self ’ as compared to the other viral proteins;
while VP2 proteins showed with 6.2% the highest degree
of homology with the host.
The functionalities of stAg have been reviewed previ-
ously [30]. The evidence collected for stAg in this paper
showed some specific features for this viral protein,
suggesting that the protein has not evolved towards a
higher percentage of “host self” (Figure 1b, 16.6% of
unique pentapeptides), and thereby maintaining an ele-
vated level of immune presentation and antibody gener-
ation against linear epitopes (Figure 2). This might be
advantageous for diagnostic purposes, but does not edu-
cate on the pathological consequences. Opposite to stAg
is the observation for VP2, for which it seems like there is
an evolution towards an ‘as high as possible’ “self” (host)
content, thereby reducing the immune response. This is
unexpected, because VP2, as minor part of the - in majo-
rity VP1 composed - viral structure, must be one of the
first proteins that are recognized by the immune system
upon infection or exposure. A potential explanation
might be that VP2 is crucial in structure and function,
and therefore has to evolve towards a protein that is not
or poorly immune-dominant (a pressure that is not or
less evident for stAg). Note that these stAg and VP2considerations were based on median values obtained
on peptide microarrays.
In a previous study [26], pentamer domains were sug-
gested to be desired motifs for eventual vaccine develop-
ment. Our results however suggest that there is already a
significant amount of antibodies build against these motifs
in healthy volunteers, and thus it seems like a redundant
approach to target unique pentamer motifs. Figure 3 also
shows that there is a large fraction of peptides without
unique pentapeptides that nevertheless showed high me-
dian signal intensity. This can be explained by either the
fact that it does not need to be unique to be an epitope, or
that the reactivity is against embedded linear epitopes that
are 6-mer, 7-mers, or longer. An antibody response against
a non-unique domain would be seen as an auto-immune
response. The recent development of antigen microarray
chip technology for detecting global patterns of anti-
body reactivities makes it possible to study the natural
autoimmune repertories within healthy humans, the so
called ‘immunological homunculus (immunculus)’ [31].
The immunculus is considered as the general network
of constitutively expressed natural auto-antibodies
against extracellular, membrane, cytoplasmic, and nu-
clear self-antigens (ubiquitous and organ-specific). The
repertoires of natural auto-antibodies are surprisingly
constant in healthy persons, independent of gender and
age, and characterized by only minimal individual
Table 1 Linear regression data on correlation plots
Penta-peptides
Slope Intercept
95% CI on slope
Virus/protein Lower Upper
all 0.17 1.55 0.14 0.18
KIV 0.27 1.46 0.23 0.31
JCV 0.20 1.56 0.15 0.24
HPyV7 0.16 1.57 0.03 0.29
MCV 0.16 1.49 0.10 0.21
TSV 0.15 1.88 0.03 0.28
WUV 0.15 1.49 0.06 0.24
HPyV9 0.14 1.92 -0.04 0.31
HPyV6 0.14 1.73 0.01 0.26
BKV 0.12 1.50 0.09 0.16
SV40 0.12 1.63 0.06 0.18
agno 0.24 1.38 0.04 0.44
VP2 0.16 1.28 0.09 0.22
LTAg 0.16 1.64 0.10 0.21
VP1 0.13 1.54 0.11 0.16
stAg 0.12 2.09 0.08 0.17
Linear regression data on correlation plots between median HS microarray
signals in function of the amount of pentapeptides with no match in the
human proteome. Values in this table were obtained by applying a robust
linear model based on the MM-type regression estimator (to control the
influence of outliers) [28,29].
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allow concluding whether the signals were against larger
epitopes, or against ‘self ’ domains and be part of the
“immunculus”. Therefore, we cannot exclude that auto-
antibodies for peptide motifs encoded in the human
proteome are responsible for the cross-reactivity (im-
munological homunculus), or that some of the micro-
array signals could be explained by non-specific binding
(see below).
Previously, it was shown that the immune reactivity of
human sera directed against native VP1 is far more im-
portant as compared to the denatured form of VP1[33,34].
The fact that peptide microarrays sometimes gave high
signals (Figures 2 and 3) is therefore at variance with the
observations made in the literature. The biological mean-
ing of the presence of antibodies against linear HPyV epi-
topes is unclear. One hypothesis might be that, besides
the viral particle that presents conformational epitopes
to the immune system, there is quite some presenta-
tion of degraded viral protein in form of small pep-
tides, and in case this is a unique motif (= unique
pentapeptide), the immune system is building a de-
tectable immune response. It is of particular import-
ance to note here that we could illustrate the presence
of antibodies against linear epitopes – mainly against
viral unique pentapeptide fraction – against not onlyVP1, but also LTAg, stAg, and VP2, proteins that are
only present as a consequence of a replication cycle
(and not merely exposure).
Obviously the large number of peptides on the micro-
array makes it impractical and technologically almost
impossible to be evaluated and/or confirmed in ELISA.
Some confirmatory examples will be published elsewhere.
In our opinion, the only way for future validation of all
these possible epitope regions is by careful selection of sig-
nificantly contributing peptides, and testing them on vali-
dated peptide microarray platforms. Despite the research
progress that has been made by using peptide microarrays
[27,35-37], there is still hesitation to use these arrays
beyond the initial screening, because of possibilities of
a-specific reactivities, lack of reliable relation between sig-
nal intensities and antibody affinities, lack of array produc-
tion reproducibility, and intra- and inter-assay variability.
In order to evaluate larger panels of donors, patients, and
certain risk groups against a large panel of HPyV peptides,
array optimization will be required. Despite this, several
other groups have tried to use peptide microarrays to
miniaturize the antigen-antibody interaction while simul-
taneously studying several peptide sequences, e.g. in
the field of GB virus C, Herpes simplex, and human
coronaviruses. They concluded that antigenic peptides
could be considered useful tools for designing new diag-
nostic systems with often sensitivities in the range of
low- picomolar concentrations of mAbs and with a high
specificity [38,39]. However, while evaluating our results,
we were absolutely aware of the shortcomings of the initial
experiments. But because the presentation of our results
was population-based, and mainly derived from the me-
dian values, the observed tendencies were considered reli-
able, and will be used for future work and confirmations.
Conclusion
In this study, in essence 2 different topics were evalu-
ated, namely: the correlation between the polyomavirus
proteome in relation to the human proteome, and the
study of a HPyV peptide microarray incubated with hu-
man plasma samples obtained from healthy subjects. A
correlation between the presence of unique pentapep-
tides motifs embedded in 15-mer peptides and the signal
obtained on the microarray was presented. Under the as-
sumption that a linear epitope could be as small as a
pentapeptide, on average 9.3% of the polyomavirus
proteome is unique and could be recognized by the host
as non-self and it is specifically against these 9.3% of
unique motifs that the immune response has been seen.
Methods and materials
Healthy subject (HS) samples
A total of 49 healthy subjects were included in this study.
For this study, the protocol and the informed consent
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Medische Ethiek – ZiekenhuisNetwork Antwerpen
(ZNA)” and approved (E.C. Approval No 3792). In-
formed consent was available for all 49. There were 28
women (age between 23 and 54 years, with mean ±
SEM = 39.8 ± 1.8), and 21 men (age between 27 and 57,
with mean ± SEM 42.6 ± 2.0). HS were selected to repre-
sent different geographical areas: 20 HS were born in
Belgium, 3 in Romania and 2 in India, 2 from – respec-
tively - South-Africa, the UK, and USA, and 1 from each
of the following countries: Burundi, China, Democratic
Republic of Congo, Egypt, Germany, Hong Kong, Israel,
Italy, Jamaica, Japan, Kenya, Macedonia, Morocco,
Slovakia, South Korea, Sri Lanka, The Netherlands, and
Ukraine. Each HS gave 50 ml of blood, and plasma was
divided in 300 μl aliquots and stored at −80°C.
Polyomavirus peptide microarrays
A peptide array representing the human polyomavirus
proteome was prepared by JPT Innovative Peptide
Solutions (Berlin, Germany), as well as all experiments
and data collection. Polyomavirus protein sequences
were retrieved from the NCBI database. The 6 best cov-
ering sequences for each protein of each virus was calcu-
lated. The following proteins were included: agnoprotein
(agno), small T antigen (stAg), large T antigen (LTAg),
VP1, VP2, VP3 of the viruses BKPyV, JCPyV, KIPyV,
WUPyV, MCPyV, and SV40. In addition, the VP1 protein
of the viruses HPyV6, HPyV7, HPyV9, and TSPyV were
also presented. For JCPyV VP1, a 100% coverage of pub-
lished variants were covered by peptides, while for all
other proteins, a coverage of at least 95% was obtained.
This resulted in an array of 4,284 15-mer peptides, over-
lapping by 11 residues. Each peptide was displayed in trip-
licates on one single array chip (3 sub-arrays). The peptide
microarray was incubated with a primary antibody or sub-
ject serum, followed by incubation with a fluorescently la-
beled secondary antibody. Read-out was done by scanning
the array by means of a fluorescent microscope. Several
control incubations (no primary antibody) and control
spots (human IgG) were included. The full procedure of
the assay was as described by the microarray provider
(JPT, Berlin, Germany). The triplicate quantitative values
for each peptide were averaged, and one single value used
for further analysis. All imaging and data manipulation
was performed as described by JPT Innovative Peptide
Solutions (Berlin, Germany). The data presented in this
manuscript are log2(test peptide/control) values, de-
rived from the original fluorescent values. Mapping
(annotations) of the peptides was done against reference
NCBI database sequences: JCPyV MAD1 (AAA82102,
AAA82101, AAA82099, and AAA82103 for LTAg,
VP1, VP2, and stAg, respectively), BKPyV Dunlop
(CAA24300, CAA24299, CAA24297, and CAA24301),SV40 (YP_003708382, YP_003708381, YP_003708379,
and YP_003708383), KIPyV CU-258 (ACB12028,
ACB12026, ACB12024, and ACB12027), WUPyV CU-302
(ACB12038, ACB12036, ACB12034, and ACB12037), and
MCPyV HF (AEM01097, AEM01098, AEM01099,
AEM01096).
Bio-informatic analysis
Each of the 4284 15-mer sequences on the polyoma pep-
tide JPT array were scanned for hits against the Uniprot
human complete proteome [http://www.uniprot.org/
uniprot/?query=organism%3a9606+AND+keyword%3a%
22Complete+proteome+%5bKW-0181%5d%22+reviewed
%3ayes&force=yes&format=fasta and motivated by http://
www.uniprot.org/faq/48] using R [40] and BioConductor
[41,42]. Every 15-mer was scanned against every human
protein and only exact matches were taken into account
to compute the number of hits. The peptide array data
were annotated with these hits and the joint information
was used for all subsequent analyses. For all analyses in-
volving micro-array intensities, the values were expressed
as log2 (sample/control). Despite the transformation, the
data still displayed slight skew (to the right). In order to
take this into account, methods that are robust against
such skew as well as outlying values have been used
throughout the analysis. Descriptive statistics were
performed using base R [40]. Comparisons of medians
made use of linear rank methods as made available in
[43]. The assessment of the relationship between pres-
ence in the human genome and signal intensity on the
microarrays made use of robust linear models with
MM-type estimators as implemented in Rousseeuw
et al., 2011 [44].
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